Jane Street’s OncoMed Pharmaceuticals, Inc. OMED Stock Holding History

Jane Street’s Portfolio OMED Stock Details OMED Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2019 Q1	–	Sell	-13,511	Closed	-$10K	–	6119
2018 Q4	$10K	Buy	+13,511	New	+$20.3K	﹤0.01%	4825
2014 Q3	–	Sell	-12,820	Closed	-$299K	–	3574
2014 Q2	$299K	Buy	+12,820	New	+$317K	﹤0.01%	1841

Other funds holding OMED

Primecap Management Pasadena, California $127B AUM 44.11% 1-Year Est. Return

BVF Inc San Francisco, California $3.14B AUM 249.53% 1-Year Est. Return

Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return

Candriam SCA Strassen, Luxembourg, Luxembourg $19.3B AUM 39.18% 1-Year Est. Return

Birchview Capital Burlington, Vermont $176M AUM 95.04% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Cannell & Co New York $3.15B AUM 30.62% 1-Year Est. Return

Acadian Asset Management Boston, Massachusetts $70.5B AUM 36% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Jane Street's OMED Position: Q1 2019 in Review

Jane Street sold out of OncoMed Pharmaceuticals, Inc. (OMED) in Q1 2019, closing a stake of 13,511 shares — an estimated $10K sold.

Jane Street first reported a position in OMED in Q2 2014 and held it in 2 quarters. The position peaked at $299K in Q2 2014. 41 funds tracked by Wall St. Rank hold OMED as of Q1 2019.

Jane Street reported no remaining OncoMed Pharmaceuticals, Inc. position as of Q1 2019 after selling out during the quarter.
Jane Street sold 13,511 OncoMed Pharmaceuticals, Inc. shares in Q1 2019, an estimated $10K.
Jane Street first reported a position in OncoMed Pharmaceuticals, Inc. in Q2 2014 and held it in 2 quarters.
Jane Street's OncoMed Pharmaceuticals, Inc. position peaked at $299K in Q2 2014.
41 funds tracked by Wall St. Rank held OncoMed Pharmaceuticals, Inc. as of Q1 2019.

Based on Jane Street's 13F filing for Q1 2019, filed 16 May 2019.